AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

被引：0
|
作者：
George A. Donzella
Dominique Schols
Steven W. Lin
José A. Esté
Kirsten A. Nagashima
Paul J. Maddon
Graham P. Allaway
Thomas P. Sakmar
Geoffrey Henson
Erik DeClercq
John P. Moore
机构：
[1] The Rockefeller University,The Aaron Diamond AIDS Research Center
[2] Katholieke Universiteit,Rega Institute for Medical Research
[3] Howard Hughes Medical Institute,undefined
[4] The Rockefeller University,undefined
[5] Progenics Pharmaceuticals,undefined
[6] AnorMED,undefined
来源：
Nature Medicine | 1998年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The bicyclam AMD3100 (formula weight 830) blocks HIV-1 entry and membrane fusion via the CXCR4 co-receptor, but not via CCR5. AMD3100 prevents monoclonal antibody 12G5 from binding to CXCR4, but has no effect on binding of monoclonal antibody 2D7 to CCR5. It also inhibits binding of the CXC-chemokine, SDF-1α, to CXCR4 and subsequent signal transduction, but does not itself cause signaling and has no effect on RANTES signaling via CCR5. Thus, AMD3100 prevents CXCR4 functioning as both a HIV-1 co-receptor and a CXC-chemokine receptor. Development of small molecule inhibitors of HIV-1 entry is feasible.
引用
收藏
页码：72 / 77
页数：5
相关论文
共 50 条
  • [1] AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
    Donzella, GA
    Schols, D
    Lin, SW
    Esté, JA
    Nagashima, KA
    Maddon, PJ
    Allaway, GP
    Sakmar, TP
    Henson, G
    De Clercq, E
    Moore, JP
    NATURE MEDICINE, 1998, 4 (01) : 72 - 77
  • [2] AMD3100/CXCR4 inhibitor
    De Clercq, Erik
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [3] Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection
    Hendrix, CW
    Collier, AC
    Lederman, MM
    Schols, D
    Pollard, RB
    Brown, S
    Jackson, JB
    Coombs, RW
    Gleshy, MJ
    Flexner, CW
    Bridger, GJ
    Badel, K
    MacFarland, RT
    Henson, GW
    Calandra, G
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (02) : 1253 - 1262
  • [4] CXCR4 receptor antagonist, AMD3100, is a potent inhibitor of HIV infection.
    De Clercq, E
    Schols, D
    Bridger, G
    Henson, G
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U5 - U5
  • [5] Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry
    Hatse, S
    Princen, K
    Vermeire, K
    Gerlach, LO
    Rosenkilde, MM
    Schwartz, TW
    Bridger, G
    De Clercq, E
    Schols, D
    FEBS LETTERS, 2003, 546 (2-3) : 300 - 306
  • [6] The role of the CXCR4 inhibitor AMD3100 in multiple myeloma (MM).
    Ghobrial, IM
    Melhem, M
    Singha, U
    George, D
    Timm, M
    Francis, L
    Alsayed, Y
    Huston, A
    Roodman, GD
    BLOOD, 2005, 106 (11) : 700A - 700A
  • [7] Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4
    Hatse, S
    Princen, K
    Bridger, G
    De Clercq, E
    Schols, D
    FEBS LETTERS, 2002, 527 (1-3) : 255 - 262
  • [8] Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury
    Saiman, Yedidya
    Jiao, JingJing
    Fiel, M. Isabel
    Friedman, Scott L.
    Aloman, Costica
    Bansal, Meena B.
    HEPATOLOGY RESEARCH, 2015, 45 (07) : 794 - 803
  • [9] V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100
    Maeda, Yosuke
    Terasawa, Hiromi
    Nakano, Yusuke
    Monde, Kazuaki
    Yusa, Keisuke
    Oka, Shinichi
    Takiguchi, Masafumi
    Harada, Shinji
    PLOS ONE, 2014, 9 (02):
  • [10] T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure
    Arakaki, R
    Tamamura, H
    Premanathan, M
    Kanbara, K
    Ramanan, S
    Mochizuki, K
    Baba, M
    Fujii, N
    Nakashima, H
    JOURNAL OF VIROLOGY, 1999, 73 (02) : 1719 - 1723
12345